Y-mAbs Therapeutics Reports Mixed Financial Results with Profitability Improvements and Sales Decline in August 2025

Y-mAbs Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reported its financial results for the quarter ending June 2025 on August 8, 2025. The company has demonstrated notable trends in its financial metrics, particularly in profitability measures. Net profit reached its highest level at USD -3.24 million, reflecting a positive trajectory over the last five periods. Similarly, operating profit also peaked at USD -5.55 million, indicating a favorable trend in operational performance. Pre-tax profit followed suit, marking its highest at USD -3.23 million, with significant growth observed compared to previous periods. Earnings per share (EPS) improved to USD -0.07, suggesting enhanced profitability for shareholders. On the cost side, raw material expenses have decreased by 0.78% year-over-year, which may contribute to an improved profit margin. However, the company faced challenges as net sales fell to USD 19.52 million, down 11.91% from the average of the previous four periods. Additionally, cash and equivalents reached a low of USD 122.6 million, indicating a decline in short-term liquidity. The debt-equity ratio also rose to -67.63%, suggesting increased reliance on borrowing for operational funding. Overall, Y-mAbs Therapeutics, Inc. has experienced evaluation changes in its financial standing, reflecting both positive developments and areas of concern. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.